Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
You dont need to become an athlete
One of the most popular longevity treatments is NAD+ infusion
Many smaller providers have closed
Improved Mobility: Increases flexibility and joint mobility, particularly important for athletes and the elderly
Overview of Glucagon-like Peptide-1 (glp-1) Receptor Agonists As research continues, the potential applications of Semaglutide may extend beyond weight management, sparking interest in its effects on metabolic disorders, cardiovascular health, and even type 2 diabetes